文献类型：期刊文献

英文题名：Development of Novel Lignin-Based Targeted Polymeric Nanoparticle Platform for Efficient Delivery of Anticancer Drugs

作者：Liu, Kefeng[1];Zheng, Dan[1];Lei, Hantian[1];Liu, Jing[1];Lei, Jiandu[1];Wang, Luying[1];Ma, Xingyuan[2]

机构：[1]Beijing Forestry Univ, Beijing Key Lab Lignocellulos Chem, Beijing 100083, Peoples R China;[2]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China

年份：2018

卷号：4

期号：5

起止页码：1730

外文期刊名：ACS BIOMATERIALS SCIENCE & ENGINEERING

收录：;EI(收录号：20182105211052);WOS:【SCI-EXPANDED(收录号:WOS:000432476200027)】；

基金：This study was supported by the National Natural Science Foundation of China (21406013; 21576029) and Beijing college students' innovation project (S201710022045).

语种：英文

外文关键词：polymeric nanoparticle; drug delivery; lignin; renewable biopolymer; self-assembly; hydroxyl camptothecin

摘要：The clinical applications of natural anticancer drugs are being restricted by poor water solubility, fast clearance in the circulation, lack of targeting to tumor cells, and poor tissue penetration. To address these problems, in this study, we developed a novel lignin-based targeted polymeric nanoparticles (NPs) platform, folic acid-polyethylene glycol-alkaline lignin conjugates (FA-PEG-AL), via self-assembly for delivery of anticancer drug (hydroxyl camptothecin, HCPT). These lignin-based nanoparticles had moderate particle size (similar to 150 nm) with a narrow size distribution (PDI < 0.1), exhibited excellent biocompatibility, high drug loading efficiency (similar to 24.2 wt % of HCPT), prolonged blood circulation time (similar to 7-fold of free HCPT), and enhanced cellular uptake (similar to 5-fold of free HCPT). Besides, the drug biodistribution study confirmed preferred accumulation of FA-PEG-AL/HCPT NPs in tumor tissue. Subsequent tumor xenograft test revealed superior tumor suppression efficacy and reduced side effects of FAPEG-AL/HCPT NPs compared with free HCPT. Therefore, the prepared lignin-based FA-PEG-AL/HCPT NPs would be a promising candidate for anticancer drugs delivery.